NCT06256419 is a NA clinical trial of GLP-1 receptor agonist in Type 2 Diabetes Mellitus, sponsored by The Affiliated Hospital of Xuzhou Medical University.

Who is sponsoring NCT06256419?

NCT06256419 is sponsored by The Affiliated Hospital of Xuzhou Medical University.

What drugs are being tested in NCT06256419?

Interventions in NCT06256419: GLP-1 receptor agonist, responders group and nonresponders group.

What condition does NCT06256419 study?

NCT06256419 studies Type 2 Diabetes Mellitus, Susceptibility, Genetic.

Is NCT06256419 still recruiting?

NCT06256419 is currently recruiting now. Last updated 18 September 2025.

Last reviewed 2025-09-18 · How we verify

NCT06256419

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DM

Recruiting now NA Last updated 18 September 2025

What this trial tests

NA trial testing GLP-1 receptor agonist in Type 2 Diabetes Mellitus in 300 participants. Currently enrolling.

Timeline

1 January 2024

Primary endpoint
31 January 2028

31 January 2028

Quick facts

Lead sponsor	The Affiliated Hospital of Xuzhou Medical University
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	300
Start date	1 January 2024
Primary completion	31 January 2028
Estimated completion	31 January 2028
Sites	1 location across China

Drugs / interventions tested

GLP-1 receptor agonist — full drug profile →
responders group and nonresponders group — full drug profile →

Conditions studied

Type 2 Diabetes Mellitus — all drugs for Type 2 Diabetes Mellitus →
Susceptibility, Genetic — all drugs for Susceptibility, Genetic →

Sponsor

The Affiliated Hospital of Xuzhou Medical University

Who can join

Adults 25 to 70, any sex, with Type 2 Diabetes Mellitus or Susceptibility, Genetic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a retrospective cohort study of patients with T2DM who were treated with exenatide twice daily as a part of their diabetes care for at least 12 months. The objective of this study is to investigate the influence of T2DM susceptibility gene polymorphisms (NOS1AP, KCNQ1, TCF7L2, WSF1, GLP-1R, etc.) on the efficacy of GLP-1 RA (exenatide, liraglutide, etc.), to identify the variables that can predict the efficacy of GLP-1 RA, and to evaluate the weight of these variables on the efficacy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of GLP-1 receptor agonist

Trials testing the same drug.

NCT06903923 — Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy · Phase 2 · recruiting
NCT06775093 — Effects of GLP-1RAs on Reproductive Outcomes in PCOS and Obesity · NA · not yet recruiting
NCT06889454 — Cardiovascular and Endothelial Markers During OGTT Before and at Six and Twelve Months Post-treatment in Women With PCOS · recruiting
NCT07309094 — Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD · recruiting
NCT06120556 — Efficacy of Glucagon-like Peptide-1 Receptor Agonists According to Type 2 Diabetes Subtypes · completed

Other recruiting trials for Type 2 Diabetes Mellitus

Currently open trials in the same condition.

NCT07351058 — A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes · Phase 3 · recruiting
NCT07373938 — Carotid Wall Texture as a Cardiovascular Risk Biomarker in Type 2 Diabetes Mellitus · recruiting
NCT07433062 — A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With · Phase 1 · recruiting
NCT07276776 — An Evaluation of the Omnipod® M System in Adults With Type 2 Diabetes · NA · active not recruiting
NCT07232537 — An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic · recruiting

Other The Affiliated Hospital of Xuzhou Medical University trials

Trials by the same sponsor.

NCT06683131 — Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Initiation Before Percutaneous Coronary · Phase 4 · not yet recruiting
NCT07295366 — Early Administration of PCSK9 Inhibitors After Thrombectomy for Atherosclerotic Acute Ischemic Stroke: A Randomized Cont · Phase 4 · recruiting
NCT07285395 — AT1019 Plus SBRT and PD-1 Inhibitor for Advanced Solid Tumors: An IIT Study · Phase 1 · recruiting
NCT07301372 — Evaluation Study of Early Administration of Evolocumab After Thrombolysis in Patients With Atherosclerotic Acute Ischemi · Phase 4 · recruiting
NCT07133776 — Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Di · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06256419 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Affiliated Hospital of Xuzhou Medical University
Last refreshed: 18 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06256419.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing